This role is pivotal for launching empasiprubart, argenx's second therapeutic asset, targeting Multifocal Motor Neuropathy patients.
Base: $196,000.00 - $269,500.00 USD annually; Bonus/Equity: Eligible for short-term and long-term incentive programs; Benefits: Comprehensive package including retirement savings and health benefits
Must-have
Nice-to-have
Not specified